Janus Henderson Group PLC Has $757.49 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Janus Henderson Group PLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,643,060 shares of the medical equipment provider’s stock after acquiring an additional 58,587 shares during the period. Janus Henderson Group PLC’s holdings in Intuitive Surgical were worth $757,489,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ISRG. State Street Corp increased its holdings in Intuitive Surgical by 1.0% in the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after purchasing an additional 162,264 shares during the period. Capital World Investors lifted its holdings in Intuitive Surgical by 1.7% during the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after buying an additional 127,526 shares during the period. Norges Bank acquired a new position in Intuitive Surgical during the 4th quarter worth about $2,856,987,000. Invesco Ltd. grew its position in shares of Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after buying an additional 611,268 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Intuitive Surgical by 9.4% in the 4th quarter. Wellington Management Group LLP now owns 3,445,880 shares of the medical equipment provider’s stock valued at $1,951,609,000 after buying an additional 294,651 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Down 2.4%

Shares of NASDAQ ISRG opened at $353.10 on Thursday. The firm has a market cap of $124.74 billion, a PE ratio of 40.45, a P/E/G ratio of 2.62 and a beta of 1.46. The company’s fifty day simple moving average is $401.70 and its 200 day simple moving average is $454.32. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The business’s revenue was up 18.4% compared to the same quarter last year. On average, equities analysts predict that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Insider Activity

In other news, SVP Iman Jeddi sold 5,625 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the completion of the sale, the senior vice president directly owned 6,463 shares in the company, valued at $2,718,014.65. This trade represents a 46.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the completion of the sale, the executive vice president directly owned 5,720 shares of the company’s stock, valued at $2,426,080.80. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 6,606 shares of company stock valued at $2,786,967. 0.60% of the stock is currently owned by company insiders.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts remain broadly optimistic about Intuitive Surgical’s long-term prospects. Reports cite an average Wall Street price target of about $484 and one target of $685, implying significant upside from recent levels. The company’s installed da Vinci system base, recurring instrument and accessory revenue, and durable demand support the bullish view. Why Wall Street Thinks Intuitive Surgical Could Rise Intuitive Surgical Price Target
• Positive Sentiment: Management’s second-quarter commentary indicated durable platform demand and higher margin guidance, suggesting that procedure growth and profitability remain structurally attractive despite near-term volatility. ISRG Q2 Earnings Call Signals Durable Demand
• Positive Sentiment: A new awareness campaign with Deion “Coach Prime” Sanders could increase patient understanding of robotic-assisted surgery and support future procedure demand. Why Intuitive Surgical Shares Rose
• Neutral Sentiment: Intuitive Surgical overhauled its bylaws governing director nominations, shareholder proposals, and special meetings. The changes may improve governance clarity but also alter shareholder participation rights; analysts view the revisions alongside the stock’s weakness as part of a potential undervaluation case. Intuitive Surgical Undervaluation and Bylaw Changes
• Neutral Sentiment: Executive vice president Mark Brosius reported two small stock sales under a pre-arranged Rule 10b5-1 plan. Because the transactions represented roughly 2% of his holdings, they are unlikely to materially change the investment case. SEC Insider Trading Filing
• Negative Sentiment: The post-earnings selloff reflects investor caution despite quarterly results that exceeded expectations. Management warned of softer U.S. procedure growth and deferred care, raising concerns about near-term utilization and valuation. Intuitive Surgical Post-Earnings Selloff ISRG Q2 Earnings Call Signals

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Raymond James Financial restated an “outperform” rating and set a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. Robert W. Baird reduced their target price on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a report on Friday, July 17th. Leerink Partners decreased their target price on shares of Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a research report on Friday, July 17th. Citigroup lowered their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. Finally, Bank of America dropped their price target on shares of Intuitive Surgical from $520.00 to $515.00 in a research report on Friday, June 12th. Twenty-one research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $517.21.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.